Latanoprost Stada (Latanoprost)

• Latanoprost belongs to the prostaglandin analog class and is employed to manage conditions that involve elevated intra‑ocular pressure.
• Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression.
• Ocular hypertension: lowers pressure to prevent conversion to glaucoma.
• Secondary open‑angle glaucoma: provides adjunctive pressure control when other therapies are insufficient.

• Latanoprost acts as an agonist at prostaglandin F2α receptors in the ciliary body, enhancing uveoscleral outflow of aqueous humor. This increased drainage lowers intra‑ocular pressure, thereby helping to protect the optic nerve from pressure‑related damage.

Latanoprost may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects

• Eye redness or hyperemia
• Increased eyelash length and thickness
• Darkening of the iris pigment
• Eye irritation or foreign‑body sensation
• Blurred vision
• Mild ocular discomfort

Serious or Rare Side Effects

• Severe eye inflammation (uveitis)
• Allergic reactions such as swelling or rash
• Unexpected rise in intra‑ocular pressure
• Macular edema leading to vision changes
• Corneal ulceration or keratitis
• Sudden loss of vision

• Before initiating therapy, clinicians should evaluate ocular health and monitor patients regularly.
• Assess baseline intra‑ocular pressure: establish a reference for treatment effect.
• Monitor iris color changes: document any pigmentation shifts.
• Avoid use during active ocular infection: may exacerbate inflammation.
• Caution in patients with a history of uveitis: risk of flare‑ups.
• Contact lens wearers: advise removal before instillation.
• Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, affecting efficacy or safety.

Major Interactions (Avoid)

• Concomitant use with other prostaglandin analog eye drops: may cause additive ocular irritation.
• Simultaneous administration of non‑steroidal anti‑inflammatory eye drops: can reduce Latanoprost's IOP‑lowering effect.
• Use with ocular anesthetics that impair corneal healing: increased risk of corneal complications.

Moderate Interactions (Monitor Closely)

• Beta‑blocker eye drops: additive IOP reduction may require monitoring.
• Alpha‑agonist eye drops: potential for excessive pressure lowering.
• Systemic carbonic anhydrase inhibitors: may enhance overall hypotensive effect.
• Anticholinergic agents: possible influence on ocular surface.
• Topical corticosteroids: may diminish Latanoprost efficacy.